A long-term analysis offers reassurance to users of the topical treatment recently approved for children down to age 2.

Roflumilast cream 0.05% was well-tolerated and effective for the long-term treatment of mild to moderate atopic dermatitis in ...

The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrounding bosakitug and the potential role of ...

Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line ...

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...

Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients ...

ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new ...

Credit: Getty Images. Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose. Recognizing the clinical diversity of ...

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...

If none of your atopic dermatitis treatments have worked, you may be experiencing burnout (or treatment fatigue). Here's what ...